Heavy Chain Disease of the Small Bowel

Area of Science:

• Gastroenterology
• Hematology
• Immunology

Background:

• Heavy chain disease (HCD) encompasses rare lymphoproliferative disorders.
• Alpha HCD, or immunoproliferative small intestinal disease (IPSID), specifically affects the small bowel.
• IPSID is characterized by the production of incomplete heavy chains of immunoglobulins.

Purpose of the Study:

• To review current knowledge on the pathogenesis, outcome, and treatment of small bowel HCD.
• To focus on alpha HCD/IPSID, detailing recent findings and future research directions.

Main Methods:

• Literature review of pathogenesis, clinical presentation, and therapeutic strategies for IPSID.
• Analysis of recent findings, including infectious links and genetic factors.
• Evaluation of the clinical spectrum and progression of IPSID.

Main Results:

• A link between Campylobacter jejuni infection and IPSID is established, though its pathogenic role is debated.
• Cytogenetic abnormalities are reported in rare cases, offering limited insight into pathogenesis.
• IPSID is typically considered pre-lymphomatous but can present as longstanding non-progressive disease, broadening its spectrum.

Conclusions:

• Understanding IPSID pathogenesis requires further investigation into infectious triggers and genetic factors.
• The clinical spectrum of IPSID is wider than previously thought, including non-progressive forms.
• Optimal treatment strategies for IPSID need continued research and evaluation.